Back
Lyell Immunopharma, Inc. 10K Form
Sell
42
LYEL
Lyell Immunopharma, Inc.
Last Price:
$25.37
Seasonality Move:
-10.45%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive LYEL News And Ratings
See the #1 stock for the next 7 days that we like better than LYEL
LYEL Financial Statistics
Sales & Book Value
| Annual Sales: | $61K |
|---|---|
| Cash Flow: | $-28.6M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $17.06 |
| Price / Book: | 1 |
Profitability
| EPS (TTM): | -19.59070 |
|---|---|
| Net Income (TTM): | $-325.7M |
| Gross Margin: | $-19.6M |
| Return on Equity: | -86.7% |
| Return on Assets: | -69.79% |
Lyell Immunopharma, Inc. Earnings Forecast
Key Lyell Immunopharma, Inc. Financial Ratios
-
The Gross Profit Margin over the past 6 years for LYEL is -32,081.97%.
-
The Selling, General & Administrative Expenses for LYEL have been equal to 85,313.11% of Gross Profit Margin.
-
The Research & Development expenses have been 249,639.34% of Revenue.
-
The Net Earning history of LYEL is -562,285.25% of Total Revenues.
-
Per Share Earnings over the last 6 years have been positive in 1 years.
Lyell Immunopharma, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | LYEL |
| Website: | lyell.com |
Debt
| Debt-to-Equity Ratio: | 0.16 |
|---|---|
| Current Ratio: | 10.3 |
| Quick Ratio: | 10.03 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
LYEL Technical Analysis vs Fundamental Analysis
Sell
42
Lyell Immunopharma, Inc. (LYEL)
is a Sell
Is Lyell Immunopharma, Inc. a Buy or a Sell?
-
Lyell Immunopharma, Inc. stock is rated a SellThe current Lyell Immunopharma, Inc. [LYEL] share price is $22.31. The Score for LYEL is 42, which is 16% below its historic median score of 50, and infers higher risk than normal.